Загрузка...
QPCT regulation by CTCF leads to sunitinib resistance in renal cell carcinoma by promoting angiogenesis
Sunitinib is widely used as a first-line treatment for advanced renal cell carcinoma (RCC). However, a number of patients with RCC who receive sunitinib develop drug resistance; and the biological mechanisms involved in resistance to sunitinib remain unclear. It has previously been suggested that th...
Сохранить в:
| Опубликовано в: : | Int J Oncol |
|---|---|
| Главные авторы: | , , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
D.A. Spandidos
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8208629/ https://ncbi.nlm.nih.gov/pubmed/34036385 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijo.2021.5228 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|